AIDO Cell 1.0
GenBio AIDeveloper-reported Virtual Cell Benchmark 1.0 spans 31 metrics across five task families; independent reproduction remains pending.
Move from early physics and deep-learning platforms to protein and genomic representations, structure prediction, generative biology, RNA, virtual cells, tissue models and integrated discovery systems.
Developer-reported Virtual Cell Benchmark 1.0 spans 31 metrics across five task families; independent reproduction remains pending.
Public AIDO.Tissue checkpoints and downstream examples are available.
Reported evaluations include THUNDER, HEST and PathoROB; cross-paper comparability remains task-specific.
Successor to Enformer; complements AlphaMissense.
Adds a design branch to the Boltz lineage.
Connects DNA sequence to tissue-specific RNA readouts.
Founder co-created AlphaFold at DeepMind.
Trained across very large species diversity.
Treats spatial context as a first-class representation.
Adds graph-native spatial representation to BioAtlas.
Part of a wave of open AF3 reimplementations (with Boltz, Chai).
Experimentally evaluated de novo antibody designs have been reported.
Evaluated on RNA structure and downstream tasks.
Trained on 270M+ cells — largest single-cell perturbation model at release.
The authors report state-of-the-art performance across four disease-relevant evaluation groups; independent reproduction should be tracked separately.
Separated from the CZI platform record in BioAtlas ontology v2.
Published in Nature Methods in 2025.
Reported strong binding across diverse target proteins.
BoltzGen extends the line toward universal binder design.
Explicitly encodes a fundamental symmetry of DNA.
Lets general LLMs 'speak' single-cell biology.
Backed by OpenAI Startup Fund and Thrive Capital.
Adds image-language representation to the pathology layer.
Acquired the EvolutionaryScale (ESM3) team in 2025.
Generated the novel esmGFP fluorescent protein.
Trained on 9.3T DNA base pairs (Evo 2).
Included in head-to-head genomic-FM benchmarking.
Bioptimus reports training across more than one million slides for current H-Optimus releases.
Technical report compares the model with AlphaFold3-class tasks.
Models local morphology and whole-slide context.
Combines sequence and structural alphabets in the input representation.
Published in Nature in 2024.
Pretrained on hundreds of thousands of whole-slide images in the published technical report.
Represents tissue morphology as reusable image embeddings.
Reviewed as a major RNA foundation-model family in 2026 surveys.
A prominent comparator in pathology foundation-model studies.
One of the largest biotech launches ever (>$1B).
Classified ~71M possible human missense variants.
Included in modern protein-LM comparisons.
Backed by Flagship Pioneering.
A major baseline in current genomic-FM benchmarking.
Trained on ~30M single-cell transcriptomes.
Architectural ancestor of Evo's StripedHyena.
InstaDeep was acquired by BioNTech.
Co-developed Evo 2 with the Arc Institute.
RFdiffusion All-Atom extends to small-molecule binders.
Trained on ~50M single cells.
Pretrained on 33M+ human cells.
A major comparator in modern single-cell foundation-model evaluations.
Open-sourced and integrated into BioNeMo.
Provides the language-model representation used by ESMFold.
~60x faster than MSA-based methods.
Underpins the IgFold antibody structure predictor.
Available through NVIDIA BioNeMo/NIM workflows.
Revealed how folding models learn during training.
OpenCRISPR-1 was AI-designed and open-sourced.
The standard partner to RFdiffusion.
The project reports pretraining on more than 23 million non-coding RNA sequences.
Uni-Mol2 scales the family to large 3D molecular pretraining corpora.
Founder previously led products at Google.
Predecessor to AlphaGenome.
IsoDDE more than doubles AF3 accuracy on hardest targets.
Distributed through NVIDIA BioNeMo.
A common protein-embedding benchmark baseline.
David Baker won the 2024 Nobel Prize in Chemistry.
MolGPS scaled molecular graph models to new sizes.
AlphaFold DB holds 200M+ predicted structures, free for all.
Targets multi-pass membrane proteins directly.
Spun out of Caltech quantum-chemistry research.
ProGen lysozymes were experimentally active.
Collects samples from extreme natural environments worldwide.
Co-founder built Google's DeepVariant.
Founded from Stanford ML + chemistry research.
Built on the Chroma generative model.
Founder Daphne Koller is a Stanford ML pioneer and Coursera co-founder.
Pioneered federated learning across hospital networks.
Founder Brendan Frey is a deep-learning pioneer.
INS018_055 was the first drug with AI-discovered target AND molecule in Phase II.
Flagged baricitinib for COVID-19; later trial-validated.
Completed the acquisition of Exscientia on 20 November 2024.
Among the first with AI-designed molecules in trials.
Robotics-driven design–test loop.
Formerly known as Atomwise.
Publicly traded AI-biotech.
One of the largest cell-engineering foundries.
Publicly traded; software used industry-wide.
The year reflects the introduction year recorded in BioAtlas. Milestones are curated summaries and should be checked against the linked primary source.